bispecific - Robuta Search

https://pubmed.ncbi.nlm.nih.gov/36198244/ Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody)... We propose here guidelines for the management of dermatological toxicities under amivantamab with a multidisciplinary approach for the proactive management of... https://www.prnewswire.com/apac/news-releases/alphamab-oncology-announced-anti-her2-bispecific-adc-jskn003-received-approval-from-cde-to-initiate-a-phase-iii-clinical-study-for-ovarian-cancer-302340070.html Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate... /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from... https://www.mdanderson.org/newsroom/research-newsroom/bispecific-antibody-dose-shows-promising-potential-for-extensive.h00-159779601.html WCLC 2025: Bispecific antibody dose shows promising potential for extensive-stage SCLC | UT MD... https://pmc.ncbi.nlm.nih.gov/articles/PMC7210316/ Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple... Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy against B-cell malignancies, yet marked vulnerability to antigen escape... car t cells https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd38-cd3-bispecific-monoclonal-antibody-gbr-1342 Definition of anti-CD38/CD3 bispecific monoclonal antibody GBR 1342 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... https://www.benzinga.com/general/biotech/21/05/21173037/bristol-myers-inks-1-6b-licensing-agreement-for-agenus-bispecific-antibody-program-in-solid-tumor Bristol Myers Inks $1.6B Licensing Agreement For Agenus' Bispecific Antibody Program In Solid... https://www.fiercebiotech.com/biotech/gilead-grabs-hold-macrogenics-bispecific-176-billion-collaboration Gilead offers $1.76B for option to MacroGenics' bispecific Oct 17, 2022 - Gilead is coughing up $1.7 billion in biobucks for licensing rights to MacroGenics phase 1 bispecific for blood cancer patients. gilead offers option macrogenics bispecific https://www.sungenbiomed.com/ Sungen: Bispecific Antibody, Bispecific Antibody Companies bispecific antibody companies https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1530583/full Frontiers | Effect of bispecific recombinant oncolytic adenovirus carrying apoptin on apoptosis of... ObjectiveIn this study, breast cancer cell line MCF-7 was infected with recombinant oncolytic adenovirus Ad-VT expressing apopsin protein, and its anti-tumou... frontiers effect bispecific recombinant https://bispecific.com/ Bispecific Antibody Summit | Oncology Event Join the leading bispecific antibody summit advancing T-cell engagers, immuno-oncology and drug discovery. bispecific antibody summit oncology event https://my.clevelandclinic.org/podcasts/cancer-advances/bispecific-antibodies-and-immunotherapy-for-aggressive-lymphomas Bispecific Antibodies and Immunotherapy for Aggressive Lymphomas | Cleveland Clinic Listen as Dr. Caimi talks about the potential of bispecific antibody combinations, including early-phase findings on glofitamab plus ICE chemotherapy for... bispecific antibodies immunotherapy aggressive lymphomas cleveland https://www.ncbi.nlm.nih.gov/mesh?Db=mesh&Cmd=ShowDetailView&TermToSearch=68018033 Antibodies, Bispecific - MeSH - NCBI antibodies bispecific mesh ncbi https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1012134 Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies |... Author summary Filoviruses, such as Ebola virus and Marburg virus (EBOV and MARV, respectively), cause severe hemorrhagic fever with a high mortality rate in... design characterization protective pan ebolavirus https://www.globenewswire.com/fr/news-release/2026/04/10/3271710/0/en/Global-Bispecific-Antibodies-Market-to-Reach-22-3-Billion-by-2030-as-Immuno-Oncology-Innovation-and-R-D-Investment-Accelerate.html Global Bispecific Antibodies Market to Reach $22.3 Billion Report provides in-depth insights into technological developments, pipeline trends, and global opportunities shaping the future of bispecific antibodies.... bispecific antibodies global market reach billion https://www.biopharmadive.com/news/regeneron-ordspono-odranextamab-european-approval/725221/ Regeneron gains European approval for bispecific lymphoma drug | BioPharma Dive Regulators in Europe granted approval based on remission rates, while the FDA sought more progress in confirmatory trials when it rejected Ordspono. regeneron gains european approval bispecific https://www.semanticscholar.org/topic/Bispecific-CD19-directed-CD3-directed-T-Cell-%5BEPC%5D/6575041 Bispecific CD19-directed CD3-directed T Cell Engager [EPC] | Semantic Scholar t cell bispecific directed engager epc https://www.nature.com/articles/s41591-026-04522-3?error=cookies_not_supported&code=aa78ed33-c6fd-4339-941b-7c966e754993 FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1... Jul 22, 2026 - Fc receptor-homolog 5 (FcRH5) is a membrane protein that is ubiquitously expressed on myeloma cells. Cevostamab is a first-in-class, FcRH5×CD3 bispecific... https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bispecific-antibody-development-programs-guidance-industry Bispecific Antibody Development Programs Guidance for Industry | FDA SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Bispecific Antibody... antibody development for industry bispecific programs guidance https://consultqd.clevelandclinic.org/bispecific-antibody-shows-deep-remission-and-low-symptom-burden-in-patients-with-relapsedrefractory-follicular-lymphoma Bispecific Antibody Promising in R/R Follicular Lymphoma Heavily pretreated patients experience improved progression-free survival and quality of life with CD20xCD3 therapy bispecific antibody promising follicular lymphoma https://aijourn.com/akeso-published-mechanism-of-action-for-cldn18-2-cd47-bispecific-antibody-ak132-for-the-first-time-at-sitc-annual-meeting/ Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time... Nov 8, 2024 - HONG KONG, Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November https://aptevotherapeutics.com/ Aptevo Therapeutics | A clinical-stage biotechnology company focused on developing novel bispecific... biotechnology company